Dracen Pharmaceuticals attracts $40 mln Series A
Baltimore-based Dracen Pharmaceuticals Inc, a developer of anticancer therapies, has raised $40 million in Series A funding. The investors included Deerfield Management.
23 March 2018•1 min read
Baltimore-based Dracen Pharmaceuticals Inc, a developer of anticancer therapies, has raised $40 million in Series A funding. The investors included Deerfield Management.
